Sophie Pelé


Sophie Pelé

National Partner

Paris | 32 rue de Monceau, Paris, France 75008
+33 1 57 57 80 98 | +33 1 57 57 80 81

| vCard | PDF

Sophie Pelé, a national partner in Dechert's Paris office, focuses on life sciences regulatory matters including public law and litigation.

Noted for her “strong regulatory expertise” by Legal 500 EMEA and author of The Life Sciences Law Review - France Chapter, Ms. Pelé has substantial experience in clinical trial, development, manufacturing or promotion agreements, licensing and distribution schemes, but also in market access transparency, lifecycle management, as well as public procurement at hospital.

Prior to joining Dechert, Ms. Pelé served as a senior associate in the competition and regulatory department of another international law firm. Her previous experience also includes working at another leading law firm in life sciences in Paris.

  • A multinational biotechnology company before the Administrative Supreme Court to seek for the cancellation of the decree expanding recommendations for therapeutic use to cases where therapeutic alternatives exist, and the decision imposing such use on one of its major products.
  • A US-based laboratory relating to clinical trials, grants, congresses, interactions with healthcare professionals and government officers.
  • An originator company before an Administrative Court in summary proceedings to challenge the generic authorization granted to a hybrid inhaled product.
  • A multinational US-based pharmaceutical product in the negotiation of a European promotion agreement.
  • A leading high tech medical devices US-based company on the antitrust and public procurement aspects of a “dual branch” business model implemented across Europe for the supply of medical devices to public hospitals.
  • A leading high tech medical devices US-based company during and further to dawn raids conducted by the French competition authorities relating to alleged bid-rigging practices.
  • A leading high tech medical devices US-based company in the interaction with the French professional medical devices association and the French authorities in charge of pricing and reimbursement.
  • A leading pharmaceutical company in the termination of a promotion and distribution agreement and the management of regulatory related matters to ensure a proper transition and avoid any shortage of product.
  • A US-based biotech company on the settling of clinical trials in France and opening of the French branch; Advising on parallel trade.

Includes matters handled at Dechert or prior to joining the firm. 

  • Sciences Po Paris
  • Paris V Descartes
  • Paris
Speaking Engagements
  • Life Sciences Academy — Paris, France (October 2, 2018) 
  • EU Pharmaceutical Law Forum, Brussels (May 15-17, 2018)

Speaker, "Dual dialogue: Off-label use and drug repurposing in the EU: where are we going?” panel. 

Read the full agenda

  • EU Pharmaceutical Law Forum, Brussels (May 16-18, 2017)

Speaker, "Dual dialogue: Market access and Managed Entry Agreements" panel.

Read the full agenda.

  • 25th Annual EU Pharmaceutical Law Forum 2016 — Informa, Brussels (May 24, 2016)

Speaker, "Transparency of clinical trial data, other regulatory data and prices" panel discussed the following: The transparency mantra; EMA's disclosure of clinical trial and regulatory data; EMA and Pari Pharma case law: T-235/15; Implications of Regulatory Data Protection (RDP) and other competitive impact; Principles of TRIPS agreements; and Transparency of prices and reimbursement status.

View the agenda »